Shorter Time to Discontinuation Due to Treatment Failure in People Living with HIV Switched to Dolutegravir Plus Either Rilpivirine or Lamivudine Compared with Integrase Inhibitor-Based Triple Therapy in a Large Spanish Cohort
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2193-6382
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Shorter Time to Discontinuation Due to Treatment Failure in People Living with HIV Switched to Dolutegravir Plus Either Rilpivirine or Lamivudine Compared with Integrase Inhibitor-Based Triple Therapy in a Large Spanish Cohort ; volume:11 ; number:3 ; day:11 ; month:4 ; year:2022 ; pages:1177-1192 ; date:6.2022
Infectious diseases and therapy ; 11, Heft 3 (11.4.2022), 1177-1192, 6.2022
- Creator
-
Teira, Ramón
Diaz-Cuervo, Helena
Aragão, Filipa
Castaño, Manuel
Romero, Alberto
Roca, Bernardino
Montero, Marta
Galindo, Maria José
Muñoz-Sánchez, Maria Jose
Espinosa, Nuria
Peraire, Joaquim
Martínez, Elisa
Fuente, Belén de la
Domingo, Pere
Deig, Elisabeth
Merino, María Dolores
Geijo, Paloma
Estrada, Vicente
Sepúlveda, María Antonia
García, Josefina
Berenguer, Juan
Currán, Adriá
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s40121-022-00630-y
- URN
-
urn:nbn:de:101:1-2022072519575153193907
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:21 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Teira, Ramón
- Diaz-Cuervo, Helena
- Aragão, Filipa
- Castaño, Manuel
- Romero, Alberto
- Roca, Bernardino
- Montero, Marta
- Galindo, Maria José
- Muñoz-Sánchez, Maria Jose
- Espinosa, Nuria
- Peraire, Joaquim
- Martínez, Elisa
- Fuente, Belén de la
- Domingo, Pere
- Deig, Elisabeth
- Merino, María Dolores
- Geijo, Paloma
- Estrada, Vicente
- Sepúlveda, María Antonia
- García, Josefina
- Berenguer, Juan
- Currán, Adriá
- SpringerLink (Online service)
Other Objects (12)
Lamivudine/dolutegravir dual therapy in HIV-infected, virologically suppressed patients
7‐Step Flow Synthesis of the HIV Integrase Inhibitor Dolutegravir
Virologically suppressed switch to Dolutegravir/Lamivudine 2-Drug regimen versus switch to commonly prescribed 3-Drug regimens in the United States
Population Pharmacokinetic Modeling of Abacavir/Dolutegravir/Lamivudine to Support a Fixed-Dose Combination in Children with HIV-1
Dolutegravir plus lamivudine versus efavirenz plus tenofovir disoproxil fumarate and lamivudine in antiretroviral-naive adults with HIV-1 infection
Shorter paths to graph algorithms
Shorter paths to graph algorithms
Shorter paths to graph algorithms
Long-term outcome of lamivudine/dolutegravir dual therapy in HIV-infected, virologically suppressed patients
A shorter path to celestial currents
Two-Drug Regimens Dolutegravir/Lamivudine and Dolutegravir/Rilpivirine Are Effective with Few Discontinuations in US Real-World Settings: Results from the TANDEM Study
Modifying dolutegravir to PrEPare for long life
Lamivudine/dolutegravir dual therapy in HIV-infected, virologically suppressed patients
7‐Step Flow Synthesis of the HIV Integrase Inhibitor Dolutegravir
Virologically suppressed switch to Dolutegravir/Lamivudine 2-Drug regimen versus switch to commonly prescribed 3-Drug regimens in the United States
Population Pharmacokinetic Modeling of Abacavir/Dolutegravir/Lamivudine to Support a Fixed-Dose Combination in Children with HIV-1
Dolutegravir plus lamivudine versus efavirenz plus tenofovir disoproxil fumarate and lamivudine in antiretroviral-naive adults with HIV-1 infection
Shorter paths to graph algorithms
Shorter paths to graph algorithms
Shorter paths to graph algorithms
Long-term outcome of lamivudine/dolutegravir dual therapy in HIV-infected, virologically suppressed patients
A shorter path to celestial currents
Two-Drug Regimens Dolutegravir/Lamivudine and Dolutegravir/Rilpivirine Are Effective with Few Discontinuations in US Real-World Settings: Results from the TANDEM Study
Modifying dolutegravir to PrEPare for long life
Lamivudine/dolutegravir dual therapy in HIV-infected, virologically suppressed patients
7‐Step Flow Synthesis of the HIV Integrase Inhibitor Dolutegravir
Virologically suppressed switch to Dolutegravir/Lamivudine 2-Drug regimen versus switch to commonly prescribed 3-Drug regimens in the United States
Population Pharmacokinetic Modeling of Abacavir/Dolutegravir/Lamivudine to Support a Fixed-Dose Combination in Children with HIV-1
Dolutegravir plus lamivudine versus efavirenz plus tenofovir disoproxil fumarate and lamivudine in antiretroviral-naive adults with HIV-1 infection
Shorter paths to graph algorithms
Shorter paths to graph algorithms
Shorter paths to graph algorithms
Long-term outcome of lamivudine/dolutegravir dual therapy in HIV-infected, virologically suppressed patients
A shorter path to celestial currents
Two-Drug Regimens Dolutegravir/Lamivudine and Dolutegravir/Rilpivirine Are Effective with Few Discontinuations in US Real-World Settings: Results from the TANDEM Study